ArticleTranslational lung cancer research2025
Re-irradiation for local recurrence after definitive stereotactic body radiotherapy for early-stage non-small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Salvage treatment for local recurrence of non-small cell lung cancer (NSCLC) after stereotactic body radiotherapy (SBRT) remains unestablished. We investigated the safety and efficacy of a second SBRT course for in-field local recurrence of NSCLC after definitive SBRT. Methods: This study included 35 patients with NSCLC who received a second SBRT course between July 2004 and August 2021. The median interval between the first and second SBRT was 24 months (range, 6-81 months). The median prescription dose was 60 Gy in eight fractions (range, 48-66 Gy) for the second SBRT. Overall survival (OS), local control (LC), progression-free survival (PFS), and toxicity after a second SBRT were assessed. Results: The median follow-up period was 29 months (range, 3-124 months). The three-year OS, LC, and PFS rates were 50%, 47%, and 34% for all 35 patients and 72% Conclusions: Re-irradiation with SBRT was safe and can be a salvage treatment option for in-field local recurrence of NSCLC, especially adenocarcinoma, after definitive SBRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.